Latest Healthcare News

Alcidion has been named the preferred supplier for University Hospitals Sussex's new Electronic Patient Record system, with a contract expected to exceed A$35 million over seven years. This deal builds on an existing partnership and marks a significant expansion for Alcidion in the UK healthcare IT market.

Hydrix Limited’s subsidiary has landed a significant A$2.5 million contract to develop SynCardia’s next-generation fully implantable Total Artificial Heart, marking a major step in advanced cardiovascular technology.

Neuren Pharmaceuticals has published promising Phase 2 trial results for NNZ-2591 in Phelan-McDermid syndrome, underpinning its ongoing Phase 3 Koala trial recruiting in the US.

CurveBeam AI has received official Chinese regulatory approval for a strategic $10 million investment from WEGO Orthopaedics, marking a major step in its expansion into Greater China. The initial $4 million tranche at a premium share price is expected imminently, underpinning a decade-long commercialisation deal.

UC San Diego Health has begun clinical use of 4DMedical’s CT – VQ™, marking the fourth leading US academic medical centre to adopt this innovative lung imaging technology since FDA clearance. This milestone underscores 4DMedical’s rapid commercial traction and growing influence in respiratory diagnostics.

Orthocell has reported a record $3.2 million in quarterly revenue, marking its seventh consecutive quarter of growth, driven by strong sales of its Remplir™ nerve repair product in Australia and early traction in the US market.

Nexsen Limited has initiated FDA engagement for its rapid Group B Streptococcus diagnostic sensor, aiming for expedited US market entry, while bolstering its leadership team and scientific credentials.

BlinkLab Limited has secured independent scientific validation for its smartphone-based autism diagnostic technology through publication in the prestigious journal Autism Research, marking a significant milestone ahead of its FDA regulatory trial.

Biome Australia Limited has reported a record-breaking quarter and half-year sales performance, driven by strong demand for its clinically-backed probiotic products. Revenue surged over 40% compared to the previous year, defying typical seasonal slowdowns.

Next Science Limited’s shares have been suspended from ASX trading due to insufficient ongoing operations following the disposal of its main business. The suspension raises questions about the company’s future direction and compliance with listing rules.

Betashares Capital Ltd has released estimated distribution amounts for over 70 ETFs for the December 2025 period, highlighting income opportunities across a broad spectrum of funds. Investors should note key dates and the operation of the Distribution Reinvestment Plan.

Memphasys Limited has extended the repayment terms of its convertible notes with major shareholder Peters Investments to mid-2026, reinforcing financial flexibility amid ongoing commercial progress.